Portolan Capital Management, LLC Viking Therapeutics, Inc. Transaction History
Portolan Capital Management, LLC
- $1.32 Billion
- Q4 2024
A detailed history of Portolan Capital Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Portolan Capital Management, LLC holds 128,420 shares of VKTX stock, worth $3.64 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
128,420
Previous 125,762
2.11%
Holding current value
$3.64 Million
Previous $7.96 Million
35.1%
% of portfolio
0.39%
Previous 0.63%
Shares
5 transactions
Others Institutions Holding VKTX
# of Institutions
468Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$288 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$171 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$140 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$73.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.17B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...